Generic Dexone depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complement expression. Also modifies the body's immune response.
Clinical Oncology NewsLen-Dex Induction Delays Progression in Smoldering MyelomaClinical Oncology NewsSan Diego—Patients with high-risk asymptomatic multiple myeloma, characterized as smoldering multiple myeloma (SMM), can delay their time to progression with an induction regimen of lenalidomide and dexamethasone (Len-Dex), according to the results of .
Celgene announces three phase III Revlimid trials in newly diagnosed MM patients - pharmabiz.com
Celgene announces three phase III Revlimid trials in newly diagnosed MM patientspharmabiz.
Promising early results from drug combo for advanced multiple myeloma - Curetoday.com (press release)
Promising early results from drug combo for advanced multiple myelomaCuretoday.